Summary

The South Korea plasma fractionation market size reached USD 503.1 Million in 2024. The market is projected to reach USD 770.6 Million by 2033, exhibiting a growth rate (CAGR) of 4.85% during 2025-2033. The market is fueled by the increased demand for immunoglobulins and the rise in chronic disease prevalence. In addition, improvements in healthcare infrastructure and biotechnology are propelling innovations in plasma-based therapies. Also, the government support through policy initiatives to enhance blood collection and fractionation processes is providing improved accessibility of plasma-derived products to healthcare practitioners and patients, further augmenting the South Korea plasma fractionation market share.

South Korea Plasma Fractionation Market Trends:
Growing Clinical Demand for Plasma-Derived Therapies
The market is experiencing sustained growth, primarily driven by increasing clinical demand for plasma-derived medicinal products (PDMPs), particularly immunoglobulins, albumin, and coagulation factors. This demand correlates with rising incidence rates of autoimmune diseases, immunodeficiency disorders, and rare bleeding conditions, which require lifelong treatment and regular administration of fractionated plasma components. According to industry reports, South Korea has now reached the status of a "super-aged society," with citizens aged 65 and above accounting for 20% of the population. This demographic shift is intensifying demand within the market, as elderly individuals are more susceptible to immunological disorders and chronic illnesses, requiring ongoing medical intervention and plasma-derived therapies. Furthermore, as physicians and specialists increasingly adopt PDMPs in standard treatment protocols, hospitals and health systems are emphasizing consistent access to these biologics. Additionally, greater awareness and earlier diagnosis of immune-related and hematological disorders are expanding the eligible patient pool. Besides, public and private insurers are progressively including plasma-derived treatments in reimbursement programs, which improves accessibility and drives consumption. These factors collectively establish a sustained base of therapeutic demand, which is significantly contributing to the South Korea plasma fractionation market growth.
Regulatory Advancements and Quality Standardization
The regulatory environment in South Korea has undergone considerable evolution to support the growing complexity of the market. As per a nationwide South Korean study published on May 11, 2025, people diagnosed with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are found to have a substantially higher likelihood of developing autoimmune rheumatic diseases (ARDs), with risk levels elevated by factors of 5.35 and 9.13, respectively. This growing clinical association highlights an expanding patient base requiring long-term immunological support, thereby amplifying the demand for plasma-derived medicinal products. In response to such evolving healthcare needs, South Korea's regulatory authorities have intensified support for the plasma fractionation sector by streamlining approval pathways, reinforcing safety standards, and prioritizing therapies targeting autoimmune and immunodeficiency disorders. Moreover, the Ministry of Food and Drug Safety (MFDS) has implemented stringent quality and safety standards for both plasma collection and downstream processing, reflecting global best practices and aligning with international pharmacopoeias. These regulatory measures encompass viral inactivation, donor screening, and traceability protocols, enhancing overall product integrity. Also, the shift towards harmonized and science-based regulation fosters greater trust among healthcare providers and end users, encouraging the adoption of locally produced fractionated products. In addition, the increased engagement between regulators, manufacturers, and healthcare institutions also enables early risk identification and rapid response to safety concerns. In this way, South Korea's regulatory framework is not only safeguarding public health but also enhancing the global competitiveness of its plasma fractionation sector through predictable, transparent, and innovation-supportive oversight.

South Korea Plasma Fractionation Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on product, sector, application, and end user.
Product Insights:
? Immunoglobulins
? Albumin
? Coagulation Factor VIII
? Coagulation Factor IX
The report has provided a detailed breakup and analysis of the market based on the product. This Includes immunoglobulins, albumin, coagulation factor VIII, and coagulation factor IX.
Sector Insights:
? Private Sector
? Public Sector
A detailed breakup and analysis of the market based on the sector have also been provided in the report. This includes private sector and public sector.
Application Insights:
? Neurology
? Immunology
? Hematology
? Others
The report has provided a detailed breakup and analysis of the market based on the application. This includes neurology, immunology, hematology, and others.
End User Insights:
? Hospitals and Clinics
? Clinical Research Laboratories
? Academic Institutes
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics, clinical research laboratories, and academic institutes.
Regional Insights:
? Seoul Capital Area
? Yeongnam (Southeastern Region)
? Honam (Southwestern Region)
? Hoseo (Central Region)
? Others?
The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and others.

Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:
? How has the South Korea plasma fractionation market performed so far and how will it perform in the coming years?
? What is the breakup of the South Korea plasma fractionation market on the basis of product?
? What is the breakup of the South Korea plasma fractionation market on the basis of sector?
? What is the breakup of the South Korea plasma fractionation market on the basis of application?
? What is the breakup of the South Korea plasma fractionation market on the basis of end user?
? What is the breakup of the South Korea plasma fractionation market on the basis of region?
? What are the various stages in the value chain of the South Korea plasma fractionation market?
? What are the key driving factors and challenges in the South Korea plasma fractionation market?
? What is the structure of the South Korea plasma fractionation market and who are the key players?
? What is the degree of competition in the South Korea plasma fractionation market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 South Korea Plasma Fractionation Market - Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 South Korea Plasma Fractionation Market Landscape
5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)
6 South Korea Plasma Fractionation Market - Breakup by Product
6.1 Immunoglobulins
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2019-2024)
6.1.3 Market Forecast (2025-2033)
6.2 Albumin
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2019-2024)
6.2.3 Market Forecast (2025-2033)
6.3 Coagulation Factor VIII
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2019-2024)
6.3.3 Market Forecast (2025-2033)
6.4 Coagulation Factor IX
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2019-2024)
6.4.3 Market Forecast (2025-2033)
7 South Korea Plasma Fractionation Market - Breakup by Sector
7.1 Private Sector
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2019-2024)
7.1.3 Market Forecast (2025-2033)
7.2 Public Sector
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2019-2024)
7.2.3 Market Forecast (2025-2033)
8 South Korea Plasma Fractionation Market - Breakup by Application
8.1 Neurology
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2019-2024)
8.1.3 Market Forecast (2025-2033)
8.2 Immunology
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2019-2024)
8.2.3 Market Forecast (2025-2033)
8.3 Hematology
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2019-2024)
8.3.3 Market Forecast (2025-2033)
8.4 Others
8.4.1 Historical and Current Market Trends (2019-2024)
8.4.2 Market Forecast (2025-2033)
9 South Korea Plasma Fractionation Market - Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2019-2024)
9.1.3 Market Forecast (2025-2033)
9.2 Clinical Research Laboratories
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2019-2024)
9.2.3 Market Forecast (2025-2033)
9.3 Academic Institutes
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2019-2024)
9.3.3 Market Forecast (2025-2033)
10 South Korea Plasma Fractionation Market ? Breakup by Region
10.1 Seoul Capital Area
10.1.1 Overview
10.1.2 Historical and Current Market Trends (2019-2024)
10.1.3 Market Breakup by Product
10.1.4 Market Breakup by Sector
10.1.5 Market Breakup by Application
10.1.6 Market Breakup by End User
10.1.7 Key Players
10.1.8 Market Forecast (2025-2033)
10.2 Yeongnam (Southeastern Region)
10.2.1 Overview
10.2.2 Historical and Current Market Trends (2019-2024)
10.2.3 Market Breakup by Product
10.2.4 Market Breakup by Sector
10.2.5 Market Breakup by Application
10.2.6 Market Breakup by End User
10.2.7 Key Players
10.2.8 Market Forecast (2025-2033)
10.3 Honam (Southwestern Region)
10.3.1 Overview
10.3.2 Historical and Current Market Trends (2019-2024)
10.3.3 Market Breakup by Product
10.3.4 Market Breakup by Sector
10.3.5 Market Breakup by Application
10.3.6 Market Breakup by End User
10.3.7 Key Players
10.3.8 Market Forecast (2025-2033)
10.4 Hoseo (Central Region)
10.4.1 Overview
10.4.2 Historical and Current Market Trends (2019-2024)
10.4.3 Market Breakup by Product
10.4.4 Market Breakup by Sector
10.4.5 Market Breakup by Application
10.4.6 Market Breakup by End User
10.4.7 Key Players
10.4.8 Market Forecast (2025-2033)
10.5 Others
10.5.1 Historical and Current Market Trends (2019-2024)
10.5.2 Market Forecast (2025-2033)
11 South Korea Plasma Fractionation Market ? Competitive Landscape
11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant
12 Profiles of Key Players
12.1 Company A
12.1.1 Business Overview
12.1.2 Services Offered
12.1.3 Business Strategies
12.1.4 SWOT Analysis
12.1.5 Major News and Events
12.2 Company B
12.2.1 Business Overview
12.2.2 Services Offered
12.2.3 Business Strategies
12.2.4 SWOT Analysis
12.2.5 Major News and Events
12.3 Company C
12.3.1 Business Overview
12.3.2 Services Offered
12.3.3 Business Strategies
12.3.4 SWOT Analysis
12.3.5 Major News and Events
12.4 Company D
12.4.1 Business Overview
12.4.2 Services Offered
12.4.3 Business Strategies
12.4.4 SWOT Analysis
12.4.5 Major News and Events
12.5 Company E
12.5.1 Business Overview
12.5.2 Services Offered
12.5.3 Business Strategies
12.5.4 SWOT Analysis
12.5.5 Major News and Events
13 South Korea Plasma Fractionation Market - Industry Analysis
13.1 Drivers, Restraints, and Opportunities
13.1.1 Overview
13.1.2 Drivers
13.1.3 Restraints
13.1.4 Opportunities
13.2 Porters Five Forces Analysis
13.2.1 Overview
13.2.2 Bargaining Power of Buyers
13.2.3 Bargaining Power of Suppliers
13.2.4 Degree of Competition
13.2.5 Threat of New Entrants
13.2.6 Threat of Substitutes
13.3 Value Chain Analysis
14 Appendix